Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792179 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02792179 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 4 participants.
The verdict
NCT02792179, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627). This study is designed to assess the longitudinal change of Tau pathology in the brain of participants with AD using the PET ligand \[18F\]RO6958948 and to assess the safety and tolerability of PET ligand.
Interventions
- DRUG [18F]RO6958948
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-07-19 |
| Est. Completion | 2016-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792179
The ClinicalTrials.gov registry entry for NCT02792179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]RO6958948 is the first listed.
NCT02792179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02792179 about?
NCT02792179 is a clinical study titled "Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants". This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627). This study is designed to assess the longitudinal change of Tau pathology in the brain of participants with AD using the PET ligand \[18F\]RO6958948 and t...
What is the current status of trial NCT02792179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-07-19. Estimated completion is 2016-09-28.
What interventions are being tested in trial NCT02792179?
The interventions under investigation include: [18F]RO6958948 (DRUG).
Who is sponsoring clinical trial NCT02792179?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.